-
Lindau and colleagues sampled Americans aged 57 to 85 years, living independently in 2004 to learn about their sexual habits. A total of 1550 women and 1455 men were interviewed.
-
The FDA has approved the first of a new class of anti-HIV drugs. Maraviroc is a selective CCR5 co-receptor antagonist.
-
Frequent atrial premature beats predict paroxysmal atrial fibrillation in stroke patients: An opportunity for a new diagnostic strategy.
-
Elevated non-fasting triglyceride levels are associated with incident cardiovascular events independent of traditional cardiac risk factors, levels of other lipids, and markers of insulin resistance; by contrast, fasting triglyceride levels demonstrated little independent relationship to these events.
-
Compared with morbidly obese individuals who did not have surgery, those who underwent gastric bypass surgery had reduced total mortality after about 7 years, especially for deaths from diabetes, heart disease, and cancer. However, the rate of death from accidents and suicides was higher in the surgery group than in the control group.
-
Meta-analysis (META) is intended to provide greater strength of evidence by combining like populations of similar clinical trials in similar circumstances. Unfortunately, no two populations or sets of circumstances are identical, resulting in conclusions being drawn from large data sets which may not be reliable.
-
A second, orally active, endothelin receptor (ET) antagonist has been approved for the treatment of pulmonary arterial hypertension.
-
Ambulatory oxygen probably should not be routinely prescribed for patients with COPD who do not have a stable, resting arterial PaO2 less than 55 mm Hg.
-
Adding an anticoagulant to aspirin is of no value in patients with peripheral artery disease, older adults with coronary disease benefit from aggressive statin therapy, simvastatin may reduce the risk of dementia and Parkinson's disease by as much as 50%, MiraLax is safe for long-term use in patients with chronic constipation, the FDA green-lights Avandia, brings back Zelnorm for limited use, and recommends approving Evista for breast cancer prevention.
-
12-lead ECG obtained from an 81-year old woman with new onset heart failure, but no chest pain.